Method and apparatus for separating biological materials

Information

  • Patent Grant
  • 9011800
  • Patent Number
    9,011,800
  • Date Filed
    Thursday, July 16, 2009
    15 years ago
  • Date Issued
    Tuesday, April 21, 2015
    10 years ago
Abstract
According to various embodiments, a system can be provided to separate undifferentiated cells and/or stromal cells from a whole tissue sample. The whole tissue sample can be any appropriate tissue sample obtained directly from a patient. The tissue sample can be obtained during a selected operating procedure for immediate or quick application or re-application to the patient. Accordingly, autologous cells can be obtained intraoperatively for application to a patient substantially soon after obtaining a whole tissue sample.
Description
FIELD

The present disclosure is directed to a method and apparatus for separating biological materials, and particularly to a system for separating a selected fraction from a multiple-component biological material.


BACKGROUND

This section provides background information that is related to the present disclosure, but that is not necessarily prior art.


Various cellular (or biological) materials can be used to assist a healing or recovery process in a human patient. Selected cell types, such as stromal cells, pluripotent or multipotent stem cells, or fully differentiated cells, can be applied therapeutically to the patient. For example, stem cells can be applied to an affected area of the patient, such as an area that may be damaged due to injury, chemotherapy, or radiation therapy, to assist in healing the area through differentiation of the stem cells and regeneration of the affected cells.


In performing a therapeutic procedure on a human patient using undifferentiated cells, such as stem cells or stromal cells, the undifferentiated cells can be obtained from various sources, including the patient's own anatomy. Accordingly, certain autologous cells can be applied to or injected into various portions of the anatomy of the patient. Generally, a whole tissue or whole blood sample can be obtained from the patient during a first procedure, selected cells can be separated from the whole tissue or blood sample, and the selected, separated cells can be reapplied to or injected into the patient during a subsequent procedure.


SUMMARY

This section provides a general summary of aspects of the invention, and is not a comprehensive description of its full scope or all of its features.


According to various embodiments, a system can be provided to separate undifferentiated cells, including stem cells and/or stromal cells, from a whole tissue or whole blood sample. The sample can be any appropriate tissue or blood sample obtained directly from a patient. The sample can be obtained during a selected operating procedure with the object of separating undifferentiated cells from the sample for immediate or quick application to the patient. Accordingly, autologous undifferentiated cells can be obtained intra-operatively for application to a patient relatively soon after obtaining a whole tissue or whole blood sample.


Further areas of applicability will become apparent from the description provided herein. The description and specific examples are intended for purposes of illustration only and are not intended to define the scope of the claimed invention.





DRAWINGS

The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.



FIG. 1 is an elevation view of a separating system;



FIG. 2A is an exploded perspective view of a buoy system of the separating system of FIG. 1;



FIG. 2B is a cross-section view of the buoy system of FIG. 1 in plane 2B-2B;



FIG. 3 is an elevation view of a method of filling the separation system of FIG. 1;



FIG. 4 is a perspective view of a centrifuge system;



FIG. 5A is an elevation view of an operation of the buoy system of the separating system of FIG. 1 shown partially in section;



FIG. 5B is a detail view of an operation of the buoy system, shown in section, of the separating system of FIG. 1;



FIG. 6 is an elevation view of a fractionated whole tissue or whole blood sample in the separation system of FIG. 1; and



FIG. 7 is an environmental view of an application of a selected fraction of the whole tissue or whole blood sample.





Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings.


DETAILED DESCRIPTION

Example embodiments will now be described more fully with reference to the accompanying drawings.


With reference to FIG. 1, a cell separating system 20 is illustrated. The cell separating system 20 can include a container 22 of any appropriate configuration, such as a substantially cylindrical container having a cylindrical outer wall 24 and closed by a substantially circular bottom wall 26 and a substantially circular upper wall or removable cap 28. The container 22 extends along a longitudinal axis A and the top wall 28 and the bottom wall 26 are positioned separate from each other along and substantially perpendicular to the longitudinal axis A. It will be understood, however, that the container 22 can have any appropriate cross-section, such as a polygonal cross-section, a square cross-section, or any other appropriate shape.


The separating system 20 can include a buoy system 30 positionable within the container 22 and able to move generally axially along the longitudinal axis A relative to the bottom wall 26 and the top wall 28. Buoy system 30 can be configured to contact, in a desired, selected manner, an inner wall surface 32 of the wall 24. For example, the buoy system 30 can be configured to frictionally engage the inner wall surface 32 while separating system 20 is in a substantially static state, and yet move axially relatively freely with respect to the container 22 while separating system 20 is being centrifuged, as described further below. According to various embodiments, the container 22 can be formed of a material selected such that wall 24 can flex outwardly and transversely to the longitudinal axis A, under a selected force. For example, as disclosed in U.S. Pat. No. 7,374,678, issued May 20, 2008, incorporated herein by reference, the container 22 can be positioned in a centrifuge and spun so that a large force, generally several times that of gravity, is applied towards the bottom wall 26 of the container 22 so that the wall 24 flexes outwardly and container 22 compresses. In the compressed state, the cylindrical outer wall 24 can expand in diameter such that inner wall surface 32 can move radially away from the buoy system 30. Consequent clearance between buoy system 30 and inner wall surface 32 allows buoy system 30 to move axially within the container 22 and relative to the inner wall surface 32.


The buoy system 30, as discussed in further detail herein, can include or define a separation or collection volume 40 between an upper buoy portion or member 42 and a lower buoy portion or member 44. A withdrawal member or tube 46 can interconnect a withdrawal port 48 with an extraction port 50 associated with the buoy system 30. The withdrawal port 48 can extend through the top wall 28 to an exterior of the container and the extraction port 50 can communicate with and allow access to the collection volume 40 within the buoy 30. The withdrawal port 48 can include a connector, such as a luer connector 52, that can be selectively capped or blocked with a cap or plug 54.


An introduction port 56 can also extend through the top wall or cap 28 and communicate with an interior volume 57 of container 22. Introduction port 56 can also include a luer connector or an internal taper wall 58 that can interconnect with an introduction syringe 60. A cap or plug 62 can be selectively interconnected with the introduction port 56, after a material is introduced into the container 22, to cap or block luer connector 58. Also defined through the top wall or cap 28 can be a second fraction or plasma withdrawal port 64 that can include a luer lock or connector 65 and also be selectively capped or blocked with a cap or plug 66. The second fraction or plasma withdrawal port 64 can be connected with a port or bore defined through the cap 28 to withdraw or remove a material that is positioned within volume 57 between the buoy system 30 and the cap 28 at any selected time, such as after a separation step formed with the separation system 20.


With reference to FIGS. 2A and 2B, the buoy system 30 can include the extraction port 50, the upper buoy portion 42 and the lower buoy portion 44. The upper buoy portion 42 can have legs or arms 70 extending axially from an annular ring or member 72 to contact an upper transverse surface 74 of the lower buoy portion 44. The legs 70 can extend generally parallel with the longitudinal axis A of the container 22. The legs 70 can contact the upper surface 74 to help support the annular ring 72 of the upper buoy portion 42. The legs 70 can be fixed or connected to the upper surface 74 or only contact the upper surface 74 in a non-fixed manner.


The legs 70 can be formed in any appropriate configuration or number, including two legs as illustrated in FIGS. 2A and 2B, four legs, any appropriate number of legs, or any other appropriate structure, shape or configuration. For example, a colonnade can be formed near an outer edge of the first buoy portion 42 and the second buoy portion 44 to assist in holding the two portions 42, 44 apart. Regardless, the legs 70 can support the first buoy portion 42 at a selected distance from the second buoy portion 44. In yet another configuration, legs 70 can be omitted.


The annular member 72 can connect to spokes or extension members 76 extending radially from a central post or tube 78. The spokes 76 extend generally perpendicular to the axis A. The spokes, however, can extend at an angle relative to the central axis A for reduced drag, etc. The tube 78 defines an internal bore 80 that can communicate with a passage or internal bore 82 of the withdrawal port 50 to permit removal of material from the collection volume 40 of the buoy system 30. The central tube 78 includes an external wall 84 that extends axially from radial spokes 76 at a center or middle of the annular ring 72 to contact the lower buoy portion 44.


A connecting or fusion portion 86 of the central post or tube 78 can extend into and be fixed to the lower buoy portion 44 in an internal well or bore 90. The connecting portion 86 of the post 78 can be adhered, molded, fused, snap fitted, press fitted or interference fitted with the second buoy portion 44. The connection portion 86 can hold the first buoy portion 42 to the second buoy portion 44. Accordingly, the central post 78 can also assist legs 70 in holding the annular ring 72 a distance from the lower buoy portion 44 to define the collection volume 40. Alternatively, central post 78 can hold the annular ring 72 spaced from lower buoy portion 44 in the absence of legs 70.


Fins or raised portions 92 can extend upwardly from the surface 74 of the lower buoy portion 44. The fins 92 can include a ridge or notched portion 94. The central post 78 also can be fixed to the fins 92 to assist in fixing or holding the first buoy portion 42 a selected distance from the second buoy portion 44.


Lower buoy portion 44 can include upper surface 74, an annular or exterior wall 102 and a lower surface 45. The upper surface 74 of the lower buoy portion 44 can be conical and angled or inclined downwardly and inwardly from an outer circumferential edge 100 defined by the intersection or connection of the annular or exterior wall 102 and the upper surface 74. In an imaginary plane that includes longitudinal axis B of the central post 78 and that intersects the upper surface 74, axis B and the line of intersection of upper surface 74 subtend an angle α. The angle α can be any appropriate angle such as about 45° to about 90°, preferably about 75°. Alternatively, upper surface 74 can be concavely spherical rather than conical.


The central portion of the lower buoy portion 44 can define a sump or low portion 103 where a volume of material can be collected, as discussed further herein. The sump 103 can assist in forming a pellet of a selected portion of material, such as a cell fraction. The central post 78, which defines an axial bore 80, can also include a through passage that connects bore 80 in communication with an external receiving port 104 defined by outer wall 84 of post 78. The port 104 can be positioned in or at the bottom of the sump 103 to allow withdrawal of the collected material through the tube 78 and, in turn, through extraction port 50, withdrawal tube 46, and the withdraw port 48.


Positioned around the central post or tube 78 can be a valve system 110. The valve system 110 can include a sealing member 112 made of an appropriate material, such as a silicone rubber material. The sealing member 112 can be configured as a disc or washer including a central aperture, such as a round hole 113, to receive and fit around the central tube 78. A holding or valve actuation member 116 can include an upper apertured disc or washer 117 that is similar in surface area to the sealing member 112 and a mounting or holding cylinder or tube 118 that extends downwardly substantially perpendicularly from disc or washer 117. Holding cylinder 118 and washer 117 receive and fit around central tube 78 below sealing member 112. Holding cylinder 118 can also contact and be supported by the ledges 94 of fins 92 above surface 74, thereby leaving a circumferential clearance around tube 78 relative to fins 92 and holding cylinder 118 to provide communication among the wedge shaped spaces between fins 92. Briefly, the sealing member 112 and the disc 117 can form a flapper valve against the first buoy portion 42. The upper disc 117 of holding member 116 can bend to allow the sealing member 112 to move away from the first buoy portion 42, as discussed further herein and illustrated in FIG. 5B. According to various embodiments, the valve actuation member 116 can be fixed relative to the first buoy portion 42 at a central region 116a. As illustrated in FIG. 5B, at least the tube 118 and the central portion 116a of the disc 117 of the valve actuation member 116 remain substantially unmoved as a peripheral edge 112a of the sealing member 112 and a peripheral edge 117a of the disc 117 move away from the first buoy portion 42.


The height of the holding cylinder 118 can allow it to contact the ledge 94 and support the disc 117 at an appropriate elevation to hold the sealing member 112 against a bottom surface 120 of the annular member 72 when no opening force is acting on the valve portion 110. The spokes 76 can interconnect the annular member 72 with the central tube or post 78 but also form passages 122 (i.e. openings) between the spoke member 76. The passages 122, when opened by the valve system 110, allow material to move from an area above or exterior to the separation buoy system 30 into the collection volume 40.


The valve system 110 can be formed as one piece that includes both the sealing member 112 and the valve actuation member 116. For example, the sealing member 112 can be a flexible material, such as a silicone rubber, spread or applied to the disc 117 of the actuation portion 116. Alternatively, the sealing member 112 can be a separate piece that is fixed to the valve disc 117 with an adhesive or other connecting mechanism. Further, alternatively, the sealing member 112 can be separate from the valve actuation member 116 and only held in place with the biasing force of the valve actuation member 116. In other words, the sealing member 112 can be manufactured separate from the actuation member 116 or assembled together as the valve system 110.


The valve actuation member 116 can be formed of a material that can flex when a force is applied to it, such as a centrifugal force or pressure differential force, as discussed in detail herein. The material selected for the valve actuation member 116 can include acrylic, polycarbonate, and any other appropriate resilient and substantially inert material. The valve actuation member 116 can be formed of a resilient, yet flexible material. Thus, the actuation member 116 can also be referred to as a flexible member and provide a biasing or closing force on the sealing member 112 against the first buoy portion 42. The valve actuation member 116, therefore, can rebound from an open position to bias the valve 110 in the closed position.


The buoy system 30 can be made of any appropriate material and can be made of a material selected according to the biological material to be placed and separated in the separation system 20. The buoy system 30, however, can be made of materials having a mean density in the range of about 1.03 g/ml to about 1.10 g/ml, preferably in the range of about 1.045 g/ml to about 1.07 g/ml. The density or specific gravity of the buoy separation system 30 can be selected to position the collection volume 40 at an area or position within the separation container 20 relative to the material positioned in the separation system 20. The specific gravity of the buoy system 40 can be selected to move to a selected interface of two or more fractions of a separated multiple component material during separation.


For example, the second buoy portion 44 can be made of a single material or multiple materials and the upper buoy portion 42 can also be made of a single material or multiple materials. The density can be selected by selecting appropriate portions of the materials from which each of the members is made. Selecting the density of the material from which each of the elements of buoy system 30 is made, together with selecting the relative volumes, locations and dimensions of the elements, can assist in achieving a selected placement of the buoy system 30 within the material. The materials can also be selected to be substantially non-reactive to the material being separated in the system 20.


With reference to FIGS. 3-7 a method of using the separation system 20 is illustrated. Initially, a whole tissue sample 140 (e.g. bone marrow aspirate, whole blood, a combination of blood and bone marrow) is positioned within the separation system 20 via introduction from the filling syringe 60. The buoy system 30 can be positioned near the bottom wall 26 of the separation container 22 during filling. The buoy system 30 can move during a centrifugation stage, as discussed further herein.


The whole tissue sample 140 positioned in the separation system 20 can be any appropriate whole tissue sample. For example, the whole tissue sample can include whole blood, bone marrow aspirate or a mixture of whole blood and bone marrow aspirate. The whole tissue sample can include that described in U.S. Pat. No. 7,374,678, incorporated herein by reference above. The whole tissue same 140 positioned within the separation system 20, however, can be separated into selected portions or fractions and selected fractions can be withdrawn from the separation system 20.


The separation system 20 can then be positioned in a centrifuge device 150, as illustrated in FIG. 4. The centrifuge device 150 can include a centrifuge member or rotor 152 with separation wells that can hold the separation system 20 and appropriate blanks or other separation systems. The separation centrifuge 150 can include a centrifuge similar to the centrifuge sold by Biomet, Inc. with the GPS® Platelet Separation System. The separation system 20 can be spun in the centrifuge to direct a centrifugal force along the longitudinal axis A of the separation system 20 towards the bottom wall 26. During centrifugation, the materials of a multi-component material can separate based on specific gravity and density of the components. As understood by one skilled in the art, denser materials will move towards the bottom wall of the separation system 20 and lighter materials move towards the top wall 28.


As illustrated in FIGS. 5A and 5B, during centrifugation, as dense materials move towards the bottom wall 26, the buoy system 30 can move towards the top wall 28 of the separation system 20. As the buoy system 30 moves towards the top of the separation container 28, generally in the direction of arrow X, the centrifugation force and the force of a material pressing on the valve system 110 can bend edges, such as outer or peripheral edges 112a and 117a of the valve system 110. When the edges or outer portions 112a, 117a bend or move away from the under surface 120, the valve is opened or unsealed. The sealing member 112 unseals from or moves to the open position relative to the annular member 72, such as the bottom portion 120 of the annular member 72. As illustrated in FIG. 5A and in detail in 5B, when the edges 112a, 117a of the valve system 110 are bent, material can be move in the direction of arrow Y through the voids or passages 122 between the spokes 76 and into the collection volume 40.


Initially, the valve system 110 can be bent by the centrifugal forces and movement of the whole tissue sample 140 towards the collection volume 40. Then the valve 110 can remain in the open position, bent, during centrifugation due to the density difference between the denser flexible material of discs 112 and 117 and the less dense biological material, such as plasma.


Also, as discussed above, the separation container 22 can flex outwardly, allowing the buoy system 30 to move within the container 22 during centrifugation. The buoy system 30, having the selected density or specific gravity, can move within the separation container 22 to a selected interface of appropriate materials or fractions of the whole sample 140 that is being separated by the centrifugal force. Due to the flex of the container 22 a space can form between the buoy system 30 and the interior wall 32. Thus, material can also move in the direction of Y′ around the buoys system 30. The lower buoy portion 44 can include a conical lower surface 45 to assist in movement of the buoy system 30 away from the lower wall 26.


As illustrated in FIG. 6, once centrifugation has slowed sufficiently, or stopped, the valve system 110 can close with the biasing force of the actuation member 116, in the absence of the opening or external force (e.g. the centrifugal force). The buoy system 30, due to its selected density, can allow the collection volume 40 to be positioned at a selected interface within the separated sample 140. The separated whole tissue sample 140 can include at least a first fraction 140a that can be closest to the top wall 28 of the separation container 22 and a second fraction 140b that can be within the collection volume 40 of the buoy separation system 30. The second fraction 140b can flow around the buoy system 30 when the container 22 flexes. The whole sample 140 can also be separated to include a third fraction 140c that can be closest to the bottom wall 26 of a separation container 22.


After the centrifugation has stopped, the valve system 110 can close or seal the collection volume 40 from the first fraction 140a. Accordingly, during extraction or removal of the second fraction 140b within the separation or collection volume 40, the first fraction 140a will not interfere or mix with the second fraction 140b. Because the valve system 110 can assist in maintaining a physical separation of the selected fraction or second fraction 140b from the other fractions, the separated material can be maintained substantially pure and have a high yield.


Once the separation has concluded, an extraction withdraw syringe or system 160 can be used to withdraw the material or selected fraction 140b from the separation volume 40 via the interconnection of the withdrawal port 48 via the tube 46, the extraction port 50, the central post or tube 78, and the withdrawal hole 104. Once the material is withdrawn from the separation system 20, a user 170, such as a surgeon, can apply the material to a patient 180 in any appropriate manner. For example, the extraction withdrawal syringe 160 can be fitted or interconnected with a needle 182 to allow injection of the selected fraction into the patient 180. The selected fraction 140b, as discussed above, can include undifferentiated and/or stromal cells that can be applied to the patient 180 for selected purposes, such as tissue re-growth, healing, or other appropriate purposes.


Thus, the separation system 20 can allow for an introduction of autologous cells to the patient 180. The whole tissue sample 140 can be withdrawn from the patient 180 with the delivery syringe 60 during a single operative procedure. The centrifuge system 150 can be positioned in an operating room or near an operating room for appropriately timed separation of the whole tissue sample to allow for extraction withdrawal of the selected fraction 140b.


The foregoing description of the embodiments has been provided for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention. Individual elements or feature of a particular embodiment are generally not limited to that particular embodiment, but, where applicable, are interchangeable and can be used in a selected embodiment, even if not specifically shown or described. The same may also be varied in many ways. Such variations are not to be regarded as a departure from the invention, and all such modifications are intended to be included within the scope of the invention.

Claims
  • 1. A separation system to separate a multiple component material into at least two fractions, comprising: a separation container defining a volume within an interior wall, a first end wall, and a second end wall;a buoy separation system in the volume operable to move to a selected interface of the multiple component material when the multiple component material is separated, the buoy separation system including; a first buoy portion having a passage between a first side and a second side of the first buoy portion;a second buoy portion at a selected distance from the second side of the first buoy portion, wherein the selected distance defines a collection volume between the second side of the first buoy portion and the second buoy portion;a third buoy portion extending between the first buoy portion and the second buoy portion;a valve assembly extending from the third buoy portion, the valve assembly has a sealing member the is formed separate and distinct and is moveable relative to a flexible member, wherein the flexible member is positioned between the sealing member and the second buoy portion and holds the sealing member against the first buoy portion to seal the passage in the first buoy portion to separate the collection volume from a volume exterior to the collection volume on the first side of the first buoy portion;wherein the valve assembly is operable to be unsealed from the first buoy portion to allow a selected fraction to move into the collection volume.
  • 2. A separation system of claim 1, further comprising: a centrifuge system having a centrifuge bucket operable to hold the separation container and spin the separation container around a central axis of the centrifuge bucket and apply a centrifugal force along a longitudinal axis of the separation container.
  • 3. The separation system of claim 2, further comprising: a withdrawal port extending through the first end wall of the separation container; anda connection tube interconnecting the withdrawal port and the collection volume between the first buoy portion and the second buoy portion to allow withdrawal of the stromal cells when the valve assembly is sealed;wherein the buoy separation system is operable to move relative to the separation container based upon a force imparted on the buoy separation system by the multiple component material when the separation container is centrifuged in the centrifuge system.
  • 4. The separation system of claim 1, wherein each of the sealing member and the flexible member have an inner wall defining a passage to fit the valve assembly around a central tube extending from the first buoy portion into the collection volume;wherein at least a portion of the flexible member is fixed relative to the first buoy portion.
  • 5. The separation system of claim 4, further comprising: an extraction port formed through an outer wall of the central tube to allow withdrawal access to the collection volume.
  • 6. The separation system of claim 5, wherein the second buoy portion has an upper wall that defines a central sump to collect a pellet of stromal cells.
  • 7. The separation system of claim 4, wherein the flexible member has a peripheral edge spaced a distance outward from the inner wall of the flexible member, wherein the peripheral edge is configured to move to allow the sealing member to unseal from the first buoy portion.
  • 8. The separation system of claim 7, wherein the flexible member includes a first portion that is cantilevered and flexes relative to a second portion of the flexible member.
  • 9. The separation system of claim 1, wherein the interior wall of the separation container substantially defines a cylindrical volume; wherein the first buoy portion includes an annular member extending around a central post and a spoke member extending from the central post to the annular member;wherein the spoke and the annular member define the passage;wherein the valve assembly contacts the first side of the first buoy portion substantially adjacent the collection volume to seal the passage through the first buoy portion.
  • 10. A separation system including a buoy separation system to separate a multiple component material into at least a first fraction, the buoy separation system comprising: a first buoy portion having a passage between a first side and a second side of the first buoy portion;a second buoy portion spaced a selected distance from the second side of the first buoy portion, wherein the selected distance defines a collection volume between the second side of the first buoy portion and the second buoy portion; anda valve assembly having a sealing member and a flexible member, the flexible member having a central portion fixed relative to the first buoy portion and extending a dimension from the central portion to an outer edge great enough to extend substantially the entire selected distance between the first buoy portion and the second buoy portion when at least the central portion is fixed relative to the first buoy portion;wherein the flexible member holds the sealing member against the first buoy portion to seal the passage in the first buoy portion thus maintaining a separation of the collection volume from a volume exterior on the first side of the first buoy portion;wherein the valve assembly is operable to be unsealed from the first buoy portion to allow the first fraction to move into the collection volume.
  • 11. The separation system of claim 10, further comprising: a separation container having a volume defined by an interior wall, a first end wall, and a second end wall.
  • 12. The separation system of claim 11, further comprising: a withdraw port extending through the first end wall;an extraction port extending from the first buoy portion;a tube interconnecting the withdraw portion and the extraction portion; anda tube extending from the extraction portion into the collection volume.
  • 13. The separation system of claim 12, wherein the tube has an exterior wall that, at least in part, fixes the first buoy portion relative to the second buoy portion the selected distance to define the collection volume between the first buoy portion and the second buoy portion; wherein a first end of the tube extends to the first buoy portion and a second end of the tube extends to a sump defined by an upper wall of the second buoy portion.
  • 14. The separation system of claim 12, wherein the upper wall of the second buoy portion is formed at an angle relative to an axis of the tube; wherein the angle is about 45 degrees to about 90 degrees.
  • 15. The separation system of claim 10, wherein the flexible member includes a first disc portion extending radially from a central hub portion, wherein the central hub portion extends substantially the entire selected distance; wherein the sealing member is an annular member operable to be pressed against the first buoy portion by the flexible member.
  • 16. A separation system including a buoy separation system to separate a multiple component material into at least a first fraction, the buoy separation system comprising: a first buoy portion having a passage between a first side and a second side of the first buoy portion;a second buoy portion positioned at a selected distance from the second side of the first buoy portion, wherein the selected distance defines a collection volume between the second side of the first buoy portion and the second buoy portion;a third buoy portion extending between the first buoy portion and the second buoy portion; anda valve assembly having a sealing member distinct and separate from a flexible member;wherein the flexible member is between the sealing member and the second buoy portion and contacts the sealing member to engage the sealing member against the first buoy portion to seal the passage in the first buoy portion thus maintaining a separation of the collection volume from a volume exterior on the first side of the first buoy portion;wherein the valve assembly is operable to be unsealed from the first buoy portion.
  • 17. The separation system of claim 16, wherein the sealing member is substantially coextensive and directly contacts the flexible member.
  • 18. The separation system of claim 16, further comprising: a separation container having a volume defined by an interior wall, a first end wall, and a second end wall;wherein the first buoy portion, the second buoy portion, the third buoy portion, and the valve assembly are configured to be placed within the separation container to assist with separating a material also placed within the separation container.
  • 19. The separation system of claim 16, wherein the flexible member has a dimension great enough to extend the entire selected distance when contacting the second buoy portion.
  • 20. The separation system of claim 19, wherein the flexible member includes a first disc portion extending radially from the third buoy portion, wherein the third buoy portion extends substantially the entire selected distance; wherein the sealing member and the flexible member are both annular members, where the sealing member is pressed against the first buoy portion by the flexible member.
  • 21. The separation system of claim 20, wherein the flexible member applies a force between the second buoy portion and the sealing member to seal the passage of the first buoy portion.
  • 22. The separation system of claim 7, wherein the valve assembly further includes a holding cylinder to position the flexible member to contact the sealing member.
  • 23. The separation system of claim 1, wherein the valve assembly further includes a holding cylinder to position the flexible member in contact with the sealing member and to engage a holding portion that is extending from the second buoy portion wherein the holding portion forms a clearance between the holding cylinder and the second buoy portion.
  • 24. The separation system of claim 1, further comprising: a leg extending between the first buoy portion and the second buoy portion.
  • 25. The separation system of claim 10, further comprising: a fin extending from the second buoy portion, wherein a clearance between the valve assembly and the second buoy member is formed by contact of the valve assembly with the fin.
US Referenced Citations (547)
Number Name Date Kind
280820 Hickson et al. Jul 1883 A
593333 Park Nov 1897 A
1468313 Lux Sep 1923 A
1593814 Vogel Jul 1926 A
2722257 Lockhart Nov 1955 A
3013557 Pallotta Dec 1961 A
3141846 Laven, Jr. Jul 1964 A
3159159 Cohen Dec 1964 A
3300051 Mitchell Jan 1967 A
3409165 Creith Nov 1968 A
3420374 Umeda Jan 1969 A
3441143 Kudlaty Apr 1969 A
3453364 Flodin et al. Jul 1969 A
3469369 Helmke Sep 1969 A
3508653 Coleman Apr 1970 A
3545671 Ross Dec 1970 A
3583627 Wilson Jun 1971 A
3596652 Winkelman Aug 1971 A
3647070 Adler Mar 1972 A
3654925 Holderith Apr 1972 A
3661265 Greenspan May 1972 A
3706305 Berger et al. Dec 1972 A
3706306 Berger et al. Dec 1972 A
3723244 Breillatt, Jr. Mar 1973 A
3741400 Dick Jun 1973 A
3779383 Ayres Dec 1973 A
3785549 Latham, Jr. Jan 1974 A
3814248 Lawhead Jun 1974 A
3849072 Ayres Nov 1974 A
3850369 Bull et al. Nov 1974 A
3879295 Glover et al. Apr 1975 A
3887466 Ayres Jun 1975 A
3894952 Ayres Jul 1975 A
3896733 Rosenberg Jul 1975 A
3897337 Ayres Jul 1975 A
3897343 Ayres Jul 1975 A
3909419 Ayres Sep 1975 A
3929646 Adler Dec 1975 A
3931010 Ayres et al. Jan 1976 A
3931018 North, Jr. Jan 1976 A
3935113 Ayres Jan 1976 A
3937211 Merten Feb 1976 A
3941699 Ayres Mar 1976 A
3945928 Ayres Mar 1976 A
3951801 Ayres Apr 1976 A
3957654 Ayres May 1976 A
3962085 Liston et al. Jun 1976 A
3965889 Sachs Jun 1976 A
3972812 Gresl, Jr. Aug 1976 A
3982691 Schlutz Sep 1976 A
4001122 Griffin Jan 1977 A
4020831 Adler May 1977 A
4046699 Zine, Jr. Sep 1977 A
4055501 Cornell Oct 1977 A
4059108 Latham, Jr. Nov 1977 A
4066549 Oeser et al. Jan 1978 A
4077396 Wardlaw et al. Mar 1978 A
4088582 Murty et al. May 1978 A
4146172 Cullis et al. Mar 1979 A
4152270 Cornell May 1979 A
4154690 Ballies et al. May 1979 A
4159896 Levine et al. Jul 1979 A
4187979 Cullis et al. Feb 1980 A
4189385 Greenspan Feb 1980 A
4203840 Stoeppler et al. May 1980 A
4204537 Latham, Jr. May 1980 A
4225580 Rothman et al. Sep 1980 A
4229298 Bange Oct 1980 A
4269718 Persidsky May 1981 A
4294707 Ikeda et al. Oct 1981 A
4298598 Schwarz et al. Nov 1981 A
4300717 Latham, Jr. Nov 1981 A
4303193 Latham, Jr. Dec 1981 A
4314823 Rich, Jr. et al. Feb 1982 A
4322298 Persidsky Mar 1982 A
4332351 Kellogg et al. Jun 1982 A
4362567 Schwarz et al. Dec 1982 A
4364832 Ballies et al. Dec 1982 A
4377572 Schwarz et al. Mar 1983 A
4379849 Heimreid Apr 1983 A
4411794 Schwinn et al. Oct 1983 A
4414976 Schwarz et al. Nov 1983 A
4416654 Schoendorfer et al. Nov 1983 A
4417981 Nugent Nov 1983 A
4424132 Iriguchi Jan 1984 A
4427650 Stroetmann et al. Jan 1984 A
4427651 Stroetmann et al. Jan 1984 A
4442655 Stroetmann et al. Apr 1984 A
4443345 Wells Apr 1984 A
4445550 Davis et al. May 1984 A
4446021 Aufderhaar et al. May 1984 A
4453927 Sinko Jun 1984 A
4453939 Zimmerman et al. Jun 1984 A
4464167 Schoendorfer et al. Aug 1984 A
4511662 Baran et al. Apr 1985 A
4537767 Rothman et al. Aug 1985 A
RE32089 Blatt et al. Mar 1986 E
4577514 Bradley et al. Mar 1986 A
4610656 Mortensen Sep 1986 A
4617009 Ohlin et al. Oct 1986 A
4627879 Rose et al. Dec 1986 A
4631055 Redl et al. Dec 1986 A
4632761 Bowers et al. Dec 1986 A
4639316 Eldegheidy Jan 1987 A
4650678 Fuhge et al. Mar 1987 A
4655211 Sakamoto et al. Apr 1987 A
4672969 Dew Jun 1987 A
4675117 Neumann et al. Jun 1987 A
4680025 Kruger et al. Jul 1987 A
4714457 Alterbaum Dec 1987 A
4722790 Cawley et al. Feb 1988 A
4724317 Brown et al. Feb 1988 A
4735616 Eibl et al. Apr 1988 A
4735726 Duggins Apr 1988 A
4738655 Brimhall et al. Apr 1988 A
4755300 Fischel et al. Jul 1988 A
4755301 Bowers Jul 1988 A
4770779 Ichikawa et al. Sep 1988 A
4776964 Schoendorfer et al. Oct 1988 A
4818291 Iwatsuki et al. Apr 1989 A
4818386 Burns Apr 1989 A
4828710 Itoh et al. May 1989 A
4832851 Bowers et al. May 1989 A
4834890 Brown et al. May 1989 A
4839058 Cawley et al. Jun 1989 A
4844818 Smith Jul 1989 A
4846780 Galloway et al. Jul 1989 A
4846835 Grande Jul 1989 A
4850952 Figdor et al. Jul 1989 A
4853137 Ersson Aug 1989 A
4871462 Fischel et al. Oct 1989 A
4874368 Miller et al. Oct 1989 A
4877520 Burns Oct 1989 A
4879031 Panzani Nov 1989 A
4900453 Sedlmayer et al. Feb 1990 A
4902281 Avoy Feb 1990 A
4909251 Seelich Mar 1990 A
4915847 Dillon et al. Apr 1990 A
4917801 Luderer et al. Apr 1990 A
4928603 Rose et al. May 1990 A
4929242 Desecki et al. May 1990 A
4933291 Daiss et al. Jun 1990 A
4939081 Figdor et al. Jul 1990 A
4943273 Pages Jul 1990 A
4946601 Fiehler Aug 1990 A
4950220 Wells et al. Aug 1990 A
4957637 Cornell Sep 1990 A
4957638 Smith Sep 1990 A
4973168 Chan Nov 1990 A
4983157 Pober et al. Jan 1991 A
4983158 Headley Jan 1991 A
4985153 Kuroda et al. Jan 1991 A
5000970 Shanbhag et al. Mar 1991 A
5002571 O'Donnell, Jr. et al. Mar 1991 A
5019243 McEwen et al. May 1991 A
5024613 Vasconcellos et al. Jun 1991 A
5030215 Morse et al. Jul 1991 A
5030341 McEwen et al. Jul 1991 A
5039401 Columbus et al. Aug 1991 A
5045048 Kaleskas et al. Sep 1991 A
5047004 Wells Sep 1991 A
5053127 Schoendorfer et al. Oct 1991 A
5053134 Luderer et al. Oct 1991 A
5071570 Shiraki et al. Dec 1991 A
5080262 Herold et al. Jan 1992 A
5086784 Levine et al. Feb 1992 A
5100564 Pall et al. Mar 1992 A
5104375 Wolf et al. Apr 1992 A
5112484 Zuk, Jr. May 1992 A
5112490 Turpen May 1992 A
5131907 Williams et al. Jul 1992 A
5137832 Levine et al. Aug 1992 A
5141645 Shiraki et al. Aug 1992 A
5147290 Jonsson Sep 1992 A
5152905 Pall et al. Oct 1992 A
5156613 Sawyer Oct 1992 A
5165938 Knighton Nov 1992 A
5171456 Hwang et al. Dec 1992 A
5173295 Wehling et al. Dec 1992 A
5178602 Wells Jan 1993 A
5185001 Galanakis Feb 1993 A
5188583 Guigan et al. Feb 1993 A
5190057 Sarfarazi Mar 1993 A
5190759 Lindblad et al. Mar 1993 A
5197985 Caplan et al. Mar 1993 A
5203825 Haynes et al. Apr 1993 A
5204537 Bennet et al. Apr 1993 A
5206023 Hunziker et al. Apr 1993 A
5207638 Choksi et al. May 1993 A
5217426 Bacehowski et al. Jun 1993 A
5217627 Pall et al. Jun 1993 A
5219328 Morse et al. Jun 1993 A
5226877 Epstein Jul 1993 A
5226914 Caplan et al. Jul 1993 A
5234608 Duff Aug 1993 A
5236604 Fiehler Aug 1993 A
5251786 Sarrine Oct 1993 A
5258126 Pall et al. Nov 1993 A
5260420 Burnouf-Radosevich et al. Nov 1993 A
5269927 Fiehler Dec 1993 A
5271852 Luoma, II Dec 1993 A
5279825 Wehling et al. Jan 1994 A
5281342 Biesel et al. Jan 1994 A
5290552 Sierra et al. Mar 1994 A
5290918 Bui-Khac et al. Mar 1994 A
5298171 Biesel et al. Mar 1994 A
5304372 Michalski et al. Apr 1994 A
5316674 Pall et al. May 1994 A
5318524 Morse et al. Jun 1994 A
5318782 Weis-Fogh et al. Jun 1994 A
5321126 van Dommelen et al. Jun 1994 A
5322620 Brown et al. Jun 1994 A
5330974 Pines et al. Jul 1994 A
5344752 Murphy Sep 1994 A
5354483 Furse Oct 1994 A
5370221 Magnusson et al. Dec 1994 A
5370802 Brown Dec 1994 A
5372945 Alchas et al. Dec 1994 A
5376263 Fischel Dec 1994 A
5387187 Fell et al. Feb 1995 A
5393674 Levine et al. Feb 1995 A
5395923 Bui-Khac et al. Mar 1995 A
5403272 Deniega et al. Apr 1995 A
5405607 Epstein Apr 1995 A
5409833 Hu et al. Apr 1995 A
5411885 Marx May 1995 A
5417650 Gordon May 1995 A
5420250 Lontz May 1995 A
5443481 Lee Aug 1995 A
5454958 Fiehler Oct 1995 A
5456693 Conston et al. Oct 1995 A
5456885 Coleman et al. Oct 1995 A
5474687 Van Vlasselaer Dec 1995 A
5480378 Weis-Fogh et al. Jan 1996 A
5484383 Fitch, Jr. et al. Jan 1996 A
5486359 Caplan et al. Jan 1996 A
5494578 Brown et al. Feb 1996 A
5494592 Latham, Jr. et al. Feb 1996 A
5501371 Schwartz-Feldman Mar 1996 A
5505685 Antwiler Apr 1996 A
5510102 Cochrum Apr 1996 A
5520885 Coelho et al. May 1996 A
5525477 Hassouna Jun 1996 A
5533518 Vogler Jul 1996 A
5560830 Coleman et al. Oct 1996 A
5575778 Hardt et al. Nov 1996 A
5577513 Van Vlasselaer Nov 1996 A
5585007 Antanavich et al. Dec 1996 A
5588958 Cunningham et al. Dec 1996 A
5589462 Patat et al. Dec 1996 A
5601711 Sklar et al. Feb 1997 A
5601727 Bormann et al. Feb 1997 A
5603845 Holm Feb 1997 A
5607579 Latham, Jr. et al. Mar 1997 A
5614106 Payrat et al. Mar 1997 A
5618663 Delmas et al. Apr 1997 A
5632895 Tsukagoshi et al. May 1997 A
5632905 Haynes May 1997 A
5641414 Brown Jun 1997 A
5641622 Lake et al. Jun 1997 A
5643192 Hirsh et al. Jul 1997 A
5643193 Papillon et al. Jul 1997 A
5645540 Henniges et al. Jul 1997 A
5646004 Van Vlasselaer Jul 1997 A
5648223 Van Vlasselaer Jul 1997 A
5649903 Deniega et al. Jul 1997 A
5663051 Vlasselaer Sep 1997 A
5674173 Hlavinka et al. Oct 1997 A
5707331 Wells et al. Jan 1998 A
5707647 Dunn et al. Jan 1998 A
5707876 Levine Jan 1998 A
5716616 Prockop et al. Feb 1998 A
5723331 Tubo et al. Mar 1998 A
5724988 Dennehey et al. Mar 1998 A
5733466 Benebo et al. Mar 1998 A
5733545 Hood, III Mar 1998 A
5736033 Coleman et al. Apr 1998 A
5738784 Holm et al. Apr 1998 A
5738796 Bormann et al. Apr 1998 A
5750025 Holmes et al. May 1998 A
5750658 Coelho et al. May 1998 A
5762798 Wenthold et al. Jun 1998 A
5785700 Olson Jul 1998 A
5786217 Tubo et al. Jul 1998 A
5788662 Antanavich et al. Aug 1998 A
5792344 Holm Aug 1998 A
5795489 Holm et al. Aug 1998 A
5795571 Cederholm-Williams et al. Aug 1998 A
5795751 Apel Aug 1998 A
5811094 Caplan et al. Sep 1998 A
5811151 Hendriks et al. Sep 1998 A
5817519 Zelmanovic et al. Oct 1998 A
5823986 Peterson Oct 1998 A
5824084 Muschler Oct 1998 A
5830359 Knight et al. Nov 1998 A
5833866 Brown Nov 1998 A
5834418 Brazeau et al. Nov 1998 A
5837150 Langley et al. Nov 1998 A
5840502 Van Vlasselaer Nov 1998 A
5853600 McNeal et al. Dec 1998 A
5860937 Cohen Jan 1999 A
5863892 Stern et al. Jan 1999 A
5865785 Bischof Feb 1999 A
5885239 Headley et al. Mar 1999 A
5889584 Wardlaw Mar 1999 A
5895346 Wells et al. Apr 1999 A
5899874 Jonsson et al. May 1999 A
5900245 Sawhney et al. May 1999 A
5906934 Grande et al. May 1999 A
5916557 Berlowitz-Tarrant et al. Jun 1999 A
5916743 Lake et al. Jun 1999 A
5918622 Perez et al. Jul 1999 A
5924972 Turvaville et al. Jul 1999 A
5934803 Hutter Aug 1999 A
5938621 Kelly et al. Aug 1999 A
5951160 Ronk Sep 1999 A
5955032 Kelly et al. Sep 1999 A
5955436 Kunkle, Jr. Sep 1999 A
5958250 Brown et al. Sep 1999 A
5958253 Holm et al. Sep 1999 A
5961210 McCardel et al. Oct 1999 A
5980734 Itoh et al. Nov 1999 A
5980757 Brown et al. Nov 1999 A
5985315 Patat et al. Nov 1999 A
5997544 Nies et al. Dec 1999 A
6007811 Sawyer et al. Dec 1999 A
6010627 Hood, III Jan 2000 A
6011490 Tonnesen et al. Jan 2000 A
6020196 Hu et al. Feb 2000 A
6022306 Dumont et al. Feb 2000 A
6025201 Zelmanovic et al. Feb 2000 A
6027655 Holm Feb 2000 A
6049026 Muschler Apr 2000 A
6051146 Green et al. Apr 2000 A
6051147 Bischof Apr 2000 A
6053856 Hlavinka Apr 2000 A
6054122 MacPhee et al. Apr 2000 A
6063297 Antanavich et al. May 2000 A
6063624 Kandler et al. May 2000 A
6071421 Brown Jun 2000 A
6071422 Hlavinka et al. Jun 2000 A
6071423 Brown et al. Jun 2000 A
6090793 Zimmermann et al. Jul 2000 A
6096309 Prior et al. Aug 2000 A
6102843 Kelley et al. Aug 2000 A
6117425 MacPhee et al. Sep 2000 A
6123655 Fell et al. Sep 2000 A
6150163 McPherson et al. Nov 2000 A
6153113 Goodrich et al. Nov 2000 A
6183737 Zaleske et al. Feb 2001 B1
6196987 Holmes et al. Mar 2001 B1
6197325 MacPhee et al. Mar 2001 B1
6200287 Keller et al. Mar 2001 B1
6200606 Peterson et al. Mar 2001 B1
6214338 Antanavich et al. Apr 2001 B1
6221315 Giesler et al. Apr 2001 B1
6245900 Yamasaki et al. Jun 2001 B1
6264890 Boehringer et al. Jul 2001 B1
6274090 Coelho et al. Aug 2001 B1
6277961 Hock et al. Aug 2001 B1
6280400 Niermann Aug 2001 B1
6286670 Smith Sep 2001 B1
6296602 Headley Oct 2001 B1
6316247 Katz et al. Nov 2001 B1
6322785 Landesberg et al. Nov 2001 B1
6327491 Franklin et al. Dec 2001 B1
6328765 Hardwick et al. Dec 2001 B1
6334842 Hlavinka et al. Jan 2002 B1
6342157 Hood, III Jan 2002 B1
6351659 Vilsmeier Feb 2002 B1
6355239 Bruder et al. Mar 2002 B1
6368298 Beretta et al. Apr 2002 B1
6368498 Guilmette Apr 2002 B1
6398972 Blasetti et al. Jun 2002 B1
6406671 DiCesare et al. Jun 2002 B1
6409528 Bodnar Jun 2002 B1
6410344 Chung et al. Jun 2002 B1
6417004 Brady et al. Jul 2002 B1
6440444 Boyce et al. Aug 2002 B2
6444228 Baugh et al. Sep 2002 B1
6464624 Pages Oct 2002 B2
6471069 Lin et al. Oct 2002 B2
6472162 Coelho et al. Oct 2002 B1
6487992 Hollis Dec 2002 B1
6508778 Verkaart et al. Jan 2003 B1
6516953 DiCesare et al. Feb 2003 B1
6523698 Dennehey et al. Feb 2003 B1
6544162 Van Wie et al. Apr 2003 B1
6544727 Hei Apr 2003 B1
6558341 Swisher May 2003 B1
6563953 Lin et al. May 2003 B2
6596180 Baugh et al. Jul 2003 B2
6623959 Harris Sep 2003 B2
6629919 Egozy et al. Oct 2003 B2
6638503 Chitte et al. Oct 2003 B2
6676629 Andrew et al. Jan 2004 B2
6716187 Berckmans, III et al. Apr 2004 B1
6719901 Dolecek et al. Apr 2004 B2
6733471 Ericson et al. May 2004 B1
6758978 Bedell Jul 2004 B1
6764531 Hogan Jul 2004 B2
6777231 Katz et al. Aug 2004 B1
6803022 DiCesare et al. Oct 2004 B2
6811777 Mishra Nov 2004 B2
6830762 Baugh et al. Dec 2004 B2
6835353 Smith et al. Dec 2004 B2
6835377 Goldberg et al. Dec 2004 B2
RE38730 Wells et al. Apr 2005 E
6899813 Dolecek et al. May 2005 B2
6905612 Dorian et al. Jun 2005 B2
6911202 Amir et al. Jun 2005 B2
RE38757 Wells et al. Jul 2005 E
6979307 Beretta et al. Dec 2005 B2
7011644 Andrew et al. Mar 2006 B1
7077273 Ellsworth et al. Jul 2006 B2
7077827 Greenfield Jul 2006 B2
7155288 Soykan et al. Dec 2006 B2
7179391 Leach et al. Feb 2007 B2
7195606 Ballin Mar 2007 B2
7223346 Dorian et al. May 2007 B2
7273886 Olivero et al. Sep 2007 B2
7354515 Coull et al. Apr 2008 B2
7374678 Leach et al. May 2008 B2
7411006 Shanbrom Aug 2008 B2
7470371 Dorian et al. Dec 2008 B2
7531355 Rodriguez et al. May 2009 B2
7553413 Dorian et al. Jun 2009 B2
7694828 Swift et al. Apr 2010 B2
7806276 Leach et al. Oct 2010 B2
7845499 Higgins et al. Dec 2010 B2
7901584 Dorian et al. Mar 2011 B2
7914689 Higgins et al. Mar 2011 B2
7987995 Dorian et al. Aug 2011 B2
8048321 Leach et al. Nov 2011 B2
8062534 Higgins et al. Nov 2011 B2
8067534 Jagota et al. Nov 2011 B2
8567609 Landrigan et al. Oct 2013 B2
8596470 Leach et al. Dec 2013 B2
8783470 Hecker et al. Jul 2014 B2
8801586 Dorian et al. Aug 2014 B2
8808551 Leach et al. Aug 2014 B2
20010009757 Bischof et al. Jul 2001 A1
20020032112 Pages Mar 2002 A1
20020035820 Farris Mar 2002 A1
20020076400 Katz et al. Jun 2002 A1
20020082220 Hoemann et al. Jun 2002 A1
20020090711 Karlsson Jul 2002 A1
20020104808 Blasetti et al. Aug 2002 A1
20020114775 Pathak Aug 2002 A1
20020161449 Muschler Oct 2002 A1
20020169408 Beretta et al. Nov 2002 A1
20020172666 Sacchi et al. Nov 2002 A1
20020182664 Dolecek et al. Dec 2002 A1
20020192632 Hei et al. Dec 2002 A1
20030033021 Plouhar et al. Feb 2003 A1
20030033022 Plouhar et al. Feb 2003 A1
20030050709 Noth et al. Mar 2003 A1
20030050710 Petersen et al. Mar 2003 A1
20030082152 Hedrick et al. May 2003 A1
20030185803 Kadiyala et al. Oct 2003 A1
20030191429 Andrew et al. Oct 2003 A1
20030205538 Dorian et al. Nov 2003 A1
20040005246 Efthimiadis et al. Jan 2004 A1
20040013575 Stevens et al. Jan 2004 A1
20040120942 McGinnis et al. Jun 2004 A1
20040171146 Katz et al. Sep 2004 A1
20040182395 Brookman Sep 2004 A1
20040182788 Dorian et al. Sep 2004 A1
20040182795 Dorian et al. Sep 2004 A1
20040251217 Leach et al. Dec 2004 A1
20050076396 Katz et al. Apr 2005 A1
20050084961 Hedrick et al. Apr 2005 A1
20050084962 Simon Apr 2005 A1
20050109716 Leach et al. May 2005 A1
20050130301 McKay et al. Jun 2005 A1
20050145187 Gray Jul 2005 A1
20050153441 Hedrick et al. Jul 2005 A1
20050153442 Katz et al. Jul 2005 A1
20050186120 Dorian et al. Aug 2005 A1
20050196393 Shanbrom Sep 2005 A1
20050196874 Dorian et al. Sep 2005 A1
20050247715 Ellsworth et al. Nov 2005 A1
20050260174 Fraser et al. Nov 2005 A1
20050260175 Hedrick et al. Nov 2005 A1
20050282275 Katz et al. Dec 2005 A1
20060051865 Higgins et al. Mar 2006 A1
20060057693 Simon Mar 2006 A1
20060083720 Fraser et al. Apr 2006 A1
20060140923 Evangelista et al. Jun 2006 A1
20060151384 Ellsworth et al. Jul 2006 A1
20060175242 Dorian et al. Aug 2006 A1
20060175244 Dorian et al. Aug 2006 A1
20060178610 Nowakowski Aug 2006 A1
20060196885 Leach et al. Sep 2006 A1
20060243676 Swift et al. Nov 2006 A1
20060273049 Leach et al. Dec 2006 A1
20060273050 Higgins et al. Dec 2006 A1
20060278588 Woodell-May Dec 2006 A1
20070034579 Dorian et al. Feb 2007 A1
20070036768 Fraser et al. Feb 2007 A1
20070075016 Leach Apr 2007 A1
20070208321 Leach et al. Sep 2007 A1
20080011684 Dorian et al. Jan 2008 A1
20080164204 Hatamian et al. Jul 2008 A1
20080173593 Coull et al. Jul 2008 A1
20080193424 McKale et al. Aug 2008 A1
20080210645 Coull et al. Sep 2008 A1
20080217263 Higgins et al. Sep 2008 A1
20080217264 Leach et al. Sep 2008 A1
20080217265 Leach et al. Sep 2008 A1
20080268064 Woodell-May Oct 2008 A1
20080269762 Simon et al. Oct 2008 A1
20080283474 Leach et al. Nov 2008 A1
20080306431 Yoo Dec 2008 A1
20080318317 Roche et al. Dec 2008 A1
20090014391 Leach et al. Jan 2009 A1
20090018313 Shanbrom Jan 2009 A1
20090101599 Dorian et al. Apr 2009 A1
20090192528 Higgins et al. Jul 2009 A1
20090220482 Higgins et al. Sep 2009 A1
20090221075 Dorian et al. Sep 2009 A1
20090236297 Dorian et al. Sep 2009 A1
20090250413 Hoeppner Oct 2009 A1
20090253566 Chavarria Oct 2009 A1
20090289014 Hoeppner Nov 2009 A1
20100055087 Higgins et al. Mar 2010 A1
20100140182 Chapman et al. Jun 2010 A1
20100186676 Van Der Berg Jul 2010 A1
20100206798 Dorian et al. Aug 2010 A1
20100256595 Leach et al. Oct 2010 A1
20100323870 Leach et al. Dec 2010 A1
20100324450 Leach et al. Dec 2010 A1
20110020196 Grippi et al. Jan 2011 A1
20110021334 Leach et al. Jan 2011 A1
20110036786 Ellsworth Feb 2011 A1
20110056893 Leach et al. Mar 2011 A1
20110065183 Dorian et al. Mar 2011 A1
20110077596 Higgins et al. Mar 2011 A1
20110168193 Leach et al. Jul 2011 A1
20110192804 Landrigan et al. Aug 2011 A1
20110251041 Chavarria et al. Oct 2011 A1
20140051061 Landrigan et al. Feb 2014 A1
20140054246 Landrigan et al. Feb 2014 A1
20140091048 Leach et al. Apr 2014 A1
20140275497 Leach et al. Sep 2014 A1
20140349388 Dorian et al. Nov 2014 A1
20140356446 Leach et al. Dec 2014 A1
Foreign Referenced Citations (117)
Number Date Country
696278 Jan 1999 AU
9103724 Mar 1993 BR
1321138 Aug 1993 CA
2182862 Jun 1996 CA
2448415 Dec 2002 CA
2448415 Dec 2002 CA
1074709 Jul 1993 CN
1321103 Nov 2001 CN
1322146 Nov 2001 CN
103702729 Apr 2014 CN
56103 Oct 1860 DE
56103 Oct 1860 DE
1443359 Nov 1968 DE
4202667 May 1993 DE
090997 Oct 1983 EP
0102773 Mar 1984 EP
0109374 May 1984 EP
0142339 May 1985 EP
0244834 Nov 1987 EP
0244834 Nov 1987 EP
0253198 Jan 1988 EP
0295771 Dec 1988 EP
0417818 Mar 1991 EP
0534178 Mar 1993 EP
534178 Mar 1993 EP
0592242 Apr 1994 EP
1005910 Jun 2000 EP
1006360 Jun 2000 EP
1006360 Jun 2000 EP
1289618 Mar 2003 EP
1406492 Apr 2004 EP
1406492 Apr 2004 EP
1427279 Jun 2004 EP
1427279 Jun 2004 EP
1467746 Oct 2004 EP
1467746 Oct 2004 EP
1509326 Mar 2005 EP
1670315 Jun 2006 EP
1670315 Jun 2006 EP
1716901 Nov 2006 EP
854715 Nov 1960 GB
60-053845 Mar 1985 JP
60250014 Dec 1985 JP
60250014 Dec 1985 JP
2036872 Feb 1990 JP
02071747 Mar 1990 JP
2000199760 Jul 2000 JP
02129224 Oct 2000 JP
2004-305439 Nov 2004 JP
2005013783 Jan 2005 JP
200598704 Apr 2005 JP
2005524451 Aug 2005 JP
2006-305365 Nov 2006 JP
2006527025 Nov 2006 JP
2008104789 May 2008 JP
8400905 Mar 1984 WO
WO-8400905 Mar 1984 WO
8802259 Apr 1988 WO
WO-8802259 Apr 1988 WO
9010031 Sep 1990 WO
WO-9010031 Sep 1990 WO
9222312 Dec 1992 WO
WO-9222312 Dec 1992 WO
9305067 Mar 1993 WO
WO-9305067 Mar 1993 WO
9308904 May 1993 WO
WO-9308904 May 1993 WO
9407548 Apr 1994 WO
WO-9407548 Apr 1994 WO
9617871 Jun 1996 WO
9617871 Jun 1996 WO
WO-9617871 Jun 1996 WO
WO-9617871 Jun 1996 WO
9848938 Nov 1998 WO
WO-9848938 Nov 1998 WO
0061256 Oct 2000 WO
WO-0061256 Oct 2000 WO
0074713 Dec 2000 WO
WO-0074713 Dec 2000 WO
0103756 Jan 2001 WO
WO-0103756 Jan 2001 WO
0183068 Nov 2001 WO
WO-0183068 Nov 2001 WO
0238610 May 2002 WO
WO-0238610 May 2002 WO
02060925 Aug 2002 WO
WO-02060925 Aug 2002 WO
02098566 Dec 2002 WO
WO-02098566 Dec 2002 WO
03015800 Feb 2003 WO
WO-03015800 Feb 2003 WO
03024215 Mar 2003 WO
WO-03024215 Mar 2003 WO
03053362 Jul 2003 WO
WO-03053362 Jul 2003 WO
03088905 Oct 2003 WO
WO-03088905 Oct 2003 WO
03092894 Nov 2003 WO
WO-03092894 Nov 2003 WO
03099412 Dec 2003 WO
WO-03099412 Dec 2003 WO
2004009207 Jan 2004 WO
WO-2004009207 Jan 2004 WO
2004104553 Dec 2004 WO
WO-2004104553 Dec 2004 WO
2005034843 Apr 2005 WO
WO-2005034843 Apr 2005 WO
WO-2006041406 Apr 2006 WO
2007127834 Nov 2007 WO
WO-2007127834 Nov 2007 WO
2007142908 Dec 2007 WO
WO-2007142908 Dec 2007 WO
WO-2008127639 Oct 2008 WO
2009021257 Feb 2009 WO
WO-2009021257 Feb 2009 WO
WO-2009111338 Sep 2009 WO
WO-2011008836 Jan 2011 WO
Non-Patent Literature Citations (228)
Entry
Clayden J D Et Al: “Improved segmentation reproducibility in group tractography using a quantitative tract similarity measure” Neuroimage, Academic Press, Orlando, FL, US LNKD-DOI: 10.1016/J.Neuroimage. 2006.07.016, vol. 33, No. 2, Nov. 1, 2006, pp. 482-492.
De Wit, et al. “Experiments on the Preparation of Blood Components with the IBM 2991 Blood Cell Processor” Vox Sang. 29: 352-362 (Feb. 10, 1975).
Ehricke H H Et Al: “Visualizing MR diffusion tensor fields by dynamic fiber tracking and uncertainty mapping” Computers and Graphics, Elsevvier, GB LNKD-DOI: 10.1016/J. Cag.2006.01.031, vol. 30, No. 2, Apr. 1, 2006, pp. 255-264.
European Communication Pursuant to Article 94(3) EPC mailed May 6, 2013 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
International Preliminary Report on Patentability and Written Opinion mailed Oct. 31, 2013 for PCT/US2012/034104 claiming benefit of U.S. Appl. No. 13/089,591, filed Apr. 19, 2011.
International Search Report and Written Opinion mailed Dec. 5, 2013 for PCT/US2013/056793 claiming benefit of U.S. Appl. No. 13/595,461, filed Aug. 27, 2012.
International Search Report for PCT/US2012/034104 mailed Oct. 29, 2012, claiming benefit of U.S. Appl. No. 13/089,591, filed Apr. 18, 2012.
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee mailed Aug. 6, 2012 for PCT/US2012/034104 claiming benefit of U.S. Appl. No. 13/089,591 filed Apr. 19, 2011.
Japan Office Action mailed Aug. 23, 2013 for Japan Patent Application No. 2010-503066.
Japan Office Action mailed Jan. 22, 2013 for Japan Application No. 2010-503066.
Japanese Office Action mailed May 20, 2014 for Japanese Application No. JP2012-503768.
Jones D K et al: “Confidence mapping in diffusion ensor magnetic resonance imaging tractography using a bootstrap approach” Magnetic Resonance in Medicine Wiley USA, vol. 53, No. 5, May 2005, pp. 1143-1149.
Lori N F Et Al: “Diffusion tensor fiber tracking of human brain connectivity: acquisition methods, reliability analysis and biological results” NMR in Biomedicine Wiley UK, vol. 15, No. 7-8, Nov. 2002, pp. 493-515.
Notice of Allowance mailed Mar. 24, 2011 for U.S. Appl. No. 12/101,586.
Notice of Allowance mailed Oct. 18, 2011 for U.S. Appl. No. 12/897,401.
Parchment et al., Roles for in vitro myelotoxicity tests in preclincial drug development and clinical trial planning, Toxicology Pathology, Society of Toxicological Pathologists, vol. 21, No. 2, 1993, pp. 241-250.
Lerner, R. and N. S. Binur. “Current status of surgical adhesives.” J Surg Res 48 (Feb. 1990): 165-81.
Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. “Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment.” Wein Med Woschtr 122:37 (1972): 517-523.
Moretz, W., Jr., J Shea Jr., J. R. Emmett, and J Shea. “A simple autologous fibrinogen glue for otologic surgery.” Otolaryngol Head Neck Surg 95 (Jul. 1986): 122-4.
Nakagami, Hironori, et al., “Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells,” Angiogenesis by Adipose Tissue-Derived Cells, (Dec. 2005) pp. 2542-2547, American Heart Association, Inc.
Nathan, Suresh,, et al., “Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue,” Tissue Engineering, vol. 9, No. 4 (2003) pp. 733-744 Mary Ann Liebert, Inc.
Planat-Bénard, V., et al., “Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells,” Adipose-Derived Cell Cardiomyocyte (Feb. 6, 2004) pp. 223-229 American Heart Association, Inc.
Rubin, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1423-1424.
Sanal, M. “Does fibrin glue cause foreign body reactions? [letter].” Eur J Pediatr Surg 3 (1992): 190 (1 page).
Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. “Does fibrin glue cause foreign body reactions?” Eur—r J Pediatr Surg 2 (1992): 285-6.
Schäffler, Andreas, et al., “Concise Review: Adipose Tissue-Derived Stromal Cells—Basic and Clinical Implications for Novel Cell-Based Therapies,” Tissue-Specific Stem Cells, Stem Cells® (Apr. 10, 2007) pp. 818-827 AlphaMed Press.
Semple, Elizabeth, PhD, et al. “Quality of Thrombin Produced From the Patient's Own Plasma Using the TPD™ , a New Thrombin-Processing Device.” Journal of American Society of Extra-Corporeal Technology. JECT: 2005; 37:196-200.
Sierra, D. H. “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications.” J Biomater Appl 7 (Apr. 1993): 309-52.
Takahashi, Kazutoshi et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, (Nov. 30, 2007) pp. 1-12, Elsevier Inc.
The American Journal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr., MD., et al., “Autologous Fibrin Glue: The Last Step in Operative Hemostatis”.
Weis-Fogh, U. S. “Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system.” Eur Surg Res 20 (1988): 381-9.
Wiseman, David M., David T. Rovee, and Oscar M. Alverez. “Wound Dressings: Design and Use.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 562-580. 1st ed., Vol. Philadelphia: W. B. Saunders Company, 1992.
Woodell-May, et al., “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting,” Scientific Foundation, Journal of Carniofacial Surgery 16 (5):749-756 (Sep. 2005).
“Frequently Asked Questions, 1. Kits, 2. Enzymes,” (2003) 3 pages Worthington Biochemical Corp.
“MarrowStim™ Concentration System,” brochure. Biomet Biologics Jun. 15, 2008.
Berguer, R., R. L. Staerkel, E. E. Moore, F. A. Moore, W. B. Galloway, and M. B. Mockus. “Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports.” J Trauma 31:3 (1991): 408-11.
Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. “Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors,” J Thorac Cardiovasc Surg 105: 5 (1993): 892-7.
BioCUE™ Platelet Concentration System, Jun. 2010. (2 pages).
Boomgaard, et al., “Pooled Platelet Concentrates Prepared by the Platelet-Rich-Plasma Method and Filtered with Three Different Filters and Stored for 8 Days.” Vox Sanq, vol. 68: 82-89, Feb. 1995.
Brodke, et al., “Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft”, SCR-Enriched Bone Grafts Heal Canine Segmental Defects, Journal of Orthopaedic Research (May 2006) pp. 857-866.
Casali, B., F. Rodeghiero, A. Tosetto, B. Palmieri, R. Immovilli, C. Ghedini, and P. Rivasi. “Fibrin glue from single-donation autologous plasmapheresis.” Transfusion 32:7 (1992): 641-3.
Collier, B.S. et al., “The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH”, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md. 20014, Blood, vol. 47, No. 5 (May 1976).
Connolly, “Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair,” Clinical Orthopaedics and Related Research 313:8-18 (Apr. 1995).
DelRossi, A. J., A. C. Cernaianu, R. A.Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. “Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass.” J Thorac Cardiovasc Surg 100:2 (Aug. 1990): 281-6.
Edlich, Richard F., George T. Rodeheaver, and John G. Thacker. “Surgical Devices in Wound Healing Management.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 581-600. 1st ed., Vol. Philadelphia: W.B. Saunders Company, 1992.
Epstein, G. H., R. A. Weisman, S. Zwillenberg, and A. D. Schreiber. “A new autologous fibrinogen-based adhesive for otologic surgery.” Ann Otol Rhino Laryngol 95 (May 25-26, 1985) 40-5.
First clinical results: Kuderma, H. and Helene Matras. “Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven.” Wein Klin Wochenschr 87 (Aug. 15, 1975): 495-501.
Gibble, J. W. and P. M. Ness. “Fibrin glue: the perfect operative sealant?” Transfusion 30 (1990): 741-7.
Gimble, Jeffrey M., “Adipose-Derived Stem Cells for Regenerative Medicine,” Circulation Research (May 11, 2007) pp. 1249-1260, American Heart Association, Inc.
GPS® System, “GPS® Platelet Concentrate System,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (Feb. 29, 2004) (9 pages).
GPS® II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Biomet Biologics (Jul. 15, 2006) 16 pages.
GPS® II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Cell Factor Technologies, Inc., Biomet Europe (2005) 16 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
GPS® II System, Gravitational Platelet Separation System, “User Manual,” Cell Factor Technologies, Inc., Biomet Europe [date unknown] 13 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. “Autologous whole plasma fibrin gel. Intraoperative procurement.” Arch Surg 127 (Mar. 1992): 357-9.
Harvest SmartPrep PRP-20 Procedure Pack, “Instructions for Use” (date unknown).
Hennis, H. L., W. C. Stewart, and E. K. Jeter. “Infectious disease risks of fibrin glue [letter].” Ophthalmic Surg 23 (Sep. 1992): 640.
Hom, D., et al. “Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BD in a Previously Irradiated Problem Wound.” The Laryngoscope, vol. 113 (pp. 1566-1671) Sep. 2003.
International Search Report and Written Opinion mailed Jul. 3, 2009 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078178, filed Jul. 3, 2008.
Jackson, C. M. and Y. Nemerson. “Blood coagulation.” Annu Rev Biochem 49 (1980): 765-811).
Johnstone, et al., “Autologous Mesenchymal Progenitor Cells in Articular Cartilage Repair”, Clinical Orthopaedics and Related Research 367S:S156-S162 (Oct. 1999).
Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, Helene Matras, M.D., “Fibrin Seal: The State of the Art” (1985).
Karpatkin, S., “Heterogeneity of Human Platelets. VI,, Correlation of Platelet Function with Platelet Volume”, Blood, vol. 51, No. 2 (Feb. 1978).
Kjaergard, H. K., U. S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. “A simple method of preparation of autologous fibrin glue by means of ethanol.” Surg Gynecol Obstet 175 (1992): 72-3.
Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. “Preparation of autologous fibrin glue from pericardial blood.” Ann Thorac Sur 55 (1993): 543-4.
Kumar, Vijay et al. “Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device,” Journal of American Society of Extra-Corporeal Technology. JECT: Mar. 2005:37; 390-395.
Kumar, Vijay et al. “Whole Blood Thrombin: Development of a Process for Intra-Operative Production of Human Thrombin.” Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2007; 39:18-23.
Kumar, Vijay et al., “Autologous Thrombin: Intraoperative Production From Whole Blood.” Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2008; 40:94-98.
Lasher, Lisa, M.D., “My Experience with PRP,” PowerPoint presentation, http:/Iwww.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
“MarrowStim™ Concentration Kit Peripheral Arterial Disease (PAD) Study” brochure. Web. Jul. 2, 2009 http://www.biomet.com/patients/clinical—recruitment—padstudy.cfm.
“MarrowStimä Concentration System,” brochure. Biomet Biologics Jun. 15, 2008.
International Search Report and Written Opinion mailed Oct. 8, 2010 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
“Cell Isolation Techniques, Methods and Materials, Working with Enzymes,” (2004) (9 pages) Worthington Biochemical Corp.
“Cell Isolation Theory, Tissue Types,” (2004) (5 pages) Worthington Biochemical Corp.
“Clotalyst® Autologous Clotting Factor. Would you like to have an autologous thrombin for rapid clotting and haemostasis?” Brochure. Biomet Biologics (Aug. 15, 2008).
“Cytori Celution Cell Concentrate Device,” Exhibit 14, 510(k) Summary, FDA approval K060482 (Sep. 28, 2006).
“Frequently Asked Questions, 1. Kits, 2. Engzymes,” (2003) 3 pages Worthington Biochemical Corp.
“ThermoGenesis Corp. to Supply Autologous Thrombin Kits to Biomet, Inc.,” PR Newslink: http:/tinyurl.com/4h3up. (Apr. 5, 2005) http://www.noblood.org/press-releases/2128-thermogenesis-corp-supply-autologous-thrombin-kits-biomet-inc [web accessed Sep. 27, 2011].
“Trypsinizing cells.” Bart's Cookbook, Web. Apr. 14, 2010. http://pingu.salk.edu/˜sefton/Hyper—protocols/trypsin.html.
Anesthesiology, vol. 81, No. 4, pp. 1074-1077, Oct. 1994, Hiromasa Mitsuhata, M.D., et al., “An Anaphylactic Reaction to Topical Fibrin Glue”.
Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, M.D., et al., “Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma”.
Ann Thorac Surg, vol. 56, pp. 387-389, 1993, Robert L. Quigley, M.D., et al., “Intraoperative Procurement of Autologous Fibrin Glue”.
Badiavas, et al., “Treatment of Chronic Wounds With Bone Marrow-Derived Cells,” (Reprinted) Arch Dermatol. 139:510-516 (Apr. 2003).
Bang, N.U., et al., “Plasma Protein Requirements for Human Platelet Aggregation” Ann. N.Y. Acad Sci, 201:280-299 (1972).
Berguer, R., R. L. Staerkel, E. E. Moore, F. A. Moore, W. B. Galloway, and M. B. Mockus. “Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports.” J Trauma 31 (3 1991): 408-11.
Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. “Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors,” J Thorac Cardiovasc Surg, 105 (5 1993): 892-7.
BioCUE™ Platelet Concentration System, Dec. 2010. (2 pages).
Biopolymers, vol. 27, pp. 763-774, 1988, Gerald Marx, “Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibral Association”.
Brodke, et al., “Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft”, SCR-Enriched Bone Crafts Heal Canine Segmental Defects, Journal of Orthopaedic Research (May 2006) pp. 857-866.
Casali, B., F. Rodeghiero, A. Tosetto, B. Palmieri, R. Immovilli, C. Ghedini, and P. Rivasi. “Fibrin glue from single-donation autologous plasmapheresis.” Transfusion 32 (7 1992): 641-3.
CLOTALYST™ Automatic Clotting Factor, Would you like to have an autologous thrombin for rapid clotting and haemostasis?, brochure, Biomet Biologics, Inc., Feb. 2007 (12 pages).
Collier, B.S. et al., “The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH”, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md. 20014, Blood, vol. 47, No. 5 (May), 1976.
Connolly, “Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair,” Clinical Orthopaedics and Related Research 313:8-18 (1995).
Connolly, John, M.D., et al. “Development of an Osteogenic Bone-Marrow Preparation.” The Journal of Bone and Joint Surgery, Incorporated. vol. 71-A, No. 5 (Jun. 1989) pp. 684-691.
Dallari, et al., “In Vivo Study on the Healing of Bone Defects Treated with Bone Marrow Stromal Cells, Platelet-Rich Plasma, and Freeze-Dried Bone Allografts, Alone and in Combination,” Healing of Bone Defects, Journal of Orthopaedic Research (May 2006) pp. 877-888.
De Ugarte, et al., “Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow,” Cells Tissues Organs 174:101-109 (2003).
De Ugarte, et al., “Differential Expression of Stem Cell Mobilization-Associated Molecules on Multi-Lineage Cells from Adipose Tissue and Bone Marrow,” Immunology Letters 89:267-270 (2003).
DelRossi, A. J., A. C. Cernaianu, R. A.Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. “Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass.” J Thorac Cardiovasc Surg 100 (2 1990): 281-6.
DePalma, L., et al., “The preparation of fibrinogen concentrate for use as fibrin glue by four different methods.” Transfusion (1993) vol. 33, No. 9; pp. 717-720.
DeUgarte, M.D., Daniel A., et al., “Future of Fat as Raw Material for Tissue Regneration,” (2007) pp. 215-219, Lippincott Williams & Wilkins, Inc.
DiMuzio, Paul et al., “Development of a Tissue-Engineered Bypass Graft Seeded with Stem Cells,” Vasucular, vol. 14, No. 6, (2006) pp. 338-342, BC Decker, Inc.
Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”.
Edlich, Richard F., George T. Rodeheaver, and John G. Thacker. “Surgical Devices in Wound Healing Management.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 581-600. 1st ed., Vol. Philadelphia: W.B. Saunders Company, 1992).
Eppley, et al., “Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing,” Plastic and Reconstructive Surgery, 114(6):1502-1508 (Nov. 2004).
Epstein, G. H., R. A. Weisman, S. Zwillenberg, and A. D. Schreiber. “A new autologous fibrinogen-based adhesive for otologic surgery.” Ann Otol Rhinol Laryngol 95 (1 Pt 1 1986): 40-5.
Fibrostik™ Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003.
First clinical results: Kuderma, H. and Helene Matras. “Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven.” Wein Klin Wochenschr 87 (15 1975): 495-501.
Floryan, K. et al. “Home Study Program: Intraoperative Use of Autologous Platelet-Rich and Platelet-Poor Plasma for Orthopedic Surgery Patients” vol. 80, No. 4 (Oct. 2004) p. 667-674.
Frasier, John K., et al., “Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes,” Nature Clinical Practice Cardiovascular Medicine, vol. 3, Supplement 1 (Mar. 2006) pp. S33-S37.
Friesen, M.D., Robert, et al. “Blood Conservation During Pediatric Cardiac Surgery: Ultrafiltration of the Extracorporeal Circuit Volume After Cardiopulmonary Bypass.” Anesth. Analg 1993: 77-702-7.
Galois, et al., “Cartilage Tissue Engineering: State-of-the-Art and Future Approaches,” Pathol Biol (Paris), 53(10), Dec. 2005.
Gibble, J. W. and P. M. Ness. “Fibrin glue: the perfect operative sealant?” Transfusion 30 (8 1990): 741-7.
Gimble, Jeffrey M., “Adipose-Derived Stem Cells for Regenerative Medicine,” Circulation Research (2007) pp. 1249-1260, American Heart Association, Inc.
Gomillion, Cheryl T., et al., “Stem cells and adipose tissue engineering,” Biomaterials 27, Science Direct (2006) pp. 6052-6063, Elsevier.
GPS® III System, GPS® III Platelet Separation System, Leadership through Technology, brochure, Jul. 2007 (8 sheets).
GPS® System, “GPS® Platelet Concentrate System,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) (9 pages).
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” brochure, Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 6 pages.
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
GPS®II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Cell Factor Technologies, Inc., Biomet Europe (2005) 16 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
GPS®II System, Gravitational Platelet Separation System, “User Manual,” Cell Factor Technologies, Inc., Biomet Europe [date unknown] 13 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Grove, et al., “Plasticity of Bone Marrow-Derived Stem Cells,” Stem Cells: Concise Review, 22, Jan. 2004.
Guilak, Frank, et al., “Adipose-derived adult stem cells for cartilage tissue engineering,” Biorheology 41 (2004) pp. 389-399, IOS Press.
Harris, E.L.V. Concentration of the Extract. In. Protein Purification Methods: A Practical Approach Harris, E.L.V.; Angal, S.; Editors. (1989) Publisher: (IRL Press, Oxford, UK), pp. 67-69.
Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. “Autologous whole plasma fibrin gel. Intraoperative procurement.” Arch Surg 127 (3 1992): 357-9.
Harvest SmartPrep PRP-20 Procedure Pack, “Instructions for Use”.
Harvest Technologies brochure, SmartPrep2 (2002).
Hattori, et al., “Osteogenic Potential of Human Adipose Tissue-Derived Stromal Cells as an Alternative Stem Cell Source,” Cells Tissues Organs (2004) 178:2-12 Karger.
Haynesworth, S.E. et al. “Mitogenic Stimulation of Human Mesenchymal Stem Cells by Platelet Releasate Suggests a Mechanism for Enhancement of Bone Repair by Platelet Concentrate” 48th Annual Meeting of the Orthopaedic Research Society Poster No. 0462 (2002).
Hennis, H. L., W. C. Stewart, and E. K. Jeter. “Infectious disease risks of fibrin glue [letter].” Ophthalmic Surg 23 (9 1992): 640.
Hernigou, et al., “Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Influence of the Number and Concentration of Progenitor Cells,” Journal of Bone & Joint Surgery, 87-A(7):1430-1437 (Jul. 2005).
Hom, D., et al. “Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BB in a Previously Irradiated Problem Wound.” The Laryngoscope, vol. 113 (pp. 1566-1671) Sep. 2003.
Hood, Andrew G., et al., “Perioperative Autologous Sequestration III: A New Physiologic Glue with Wound Healing Properties,” (Jan. 1993) vol. 14 pp. 126-129.
International Preliminary Examination Report and Written Opinion issued Aug. 31, 2010 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008, which priority is also claimed of said provisional case by U.S. Appl. No. 12/395,085, filed Feb. 27, 2009.
International Preliminary Report on Patentability and Written Opinion mailed Oct. 13, 2011 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
International Preliminary Report on Patentability completed Aug. 13, 2009 for PCT/US2008/004687 claiming benefit of U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
International Search Report and Written Opinion mailed Jul. 2, 2008 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
International Search Report and Written Opinion mailed Jul. 3, 2009 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008.
International Search Report and Written Opinion mailed Jul. 30, 2010 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
International Search Report and Written Opinion mailed Nov. 7, 2011 for PCT/US2011/045290 claiming benefit of U.S. Appl. No. 12/846,944, filed Jul. 30, 2010.
International Search Report for International Application No. PCT/US/0316506 mailed Oct. 13, 2003 which claims benefit of U.S. Appl. No. 60/383,013, filed May 24, 2002.
International Search Report for International Application No. PCT/US2007/012587 mailed Nov. 6, 2007 which claims benefit of U.S. Appl. No. 11/441,276, filed May 25, 2006.
Ishida, et al., “Platelet-Rich Plasma With Biodegradable Gelatin Hydrogel Promotes Rabbit Meniscal Tissue Regeneration,” 52nd Annual Meeting of the Orthopaedic Research Society Paper No. 1035, 1 page (2006).
Jackson, C. M. and Y. Nemerson. “Blood coagulation.” Annu Rev Biochem 49 (811 1980): 765-811).
Jayadev, Suprya. “Trypsinization of Adherent Cells.” Aug. 8,1991. Web. Apr. 14, 2010 http://www.duke.edu/web/ceramide/protocols/0005.html.
Johnstone, et al., “Autologous Mesenchymal Progenitor Cells in Articular Cartilage Repair”, Clinical Orthopaedics and Related Research 367S:S156-S162 (1999).
Jorgensen, et al., “Stem Cells for Repair of Cartilage and Bone: The Next Challenge in Osteoarthritis and Rheumatoid Arthritis,” Annals of Rheumatic Diseases, Aug. 2000.
Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, 1985, Helene Matras, M.D., “Fibrin Seal: The State of the Art”.
Karpatkin, S., “Heterogeneity of Human Platelets. VI., Correlation of Platelet Function with Platelet Volume”, Blood, vol. 51, No. 2 (Feb. 1978).
Kjaergard, H. K,, U. S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. “A simple method of preparation o£ autologous fibrin glue by means of ethanol.” Surg Gynecol Obstet 175 (1 1992): 72-3.
Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. “Preparation of autologous fibrin glue from pericardial blood.” Ann Thorac Sur 55 (2 1993): 543-4.
Kumar, Vijay et al. “Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device,” Journal of American Society of Extra-Corporeal Technology. JECT: 2005:37; 390-395.
Kumar, Vijay et al. “Whole Blood Thrombin: Development of a Process for Intra-Operative Production of Human Thrombin.” Journal of American Society of Extra-Corporeal Technology. JECT: 2007; 39:18-23.
Kumar, Vijay et al., “Autologous Thrombin: Intraoperative Production From Whole Blood.” Journal of American Society of Extra-Corporeal Technology. JECT: 2008; 40:94-98.
Laryngoscope vol. 99, pp. 974-976, Sep. 1989, Kyosti Laitakari, M.D., et al., “Autologous and Homologous Fibrinogen Sealants: Adhesive Strength”.
Laryngoscope, vol. 95, pp. 1074-1076, Sep. 1985, Karl H. Siedentop, M.D., et al., “Autologous Fibrin Tissue Adhesive”.
Laryngoscope, vol. 96, pp. 1062-1064, Oct. 1986, Karl H. Siedentop, M.D., et al., “Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made from Patient's Own Blood”.
Lasher, Lisa, M.D., “My Experience with PRP,” PowerPoint presentation, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Lendeckel, Stefan, et al., “Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report,” Journal of Cranio-Maxillofacial Surgery (2004) European Association for Cranio-Maxillofacial Surgery.
Lerner, R. and N. S. Binur. “Current status of surgical adhesives.” J Surg Res 48 (2 1990): 165-81.
Longas, Maria O., “An Improved Method for the Purification of Human Fibrinogen.” J. Biochem (1980) vol. 11, pp. 559-564.
Lu, et al., “Bone Marrow Mesenchymal Stem Cells: Progress in Bone/Cartilage Defect Repair,” 19(1), Jan. 2002.
Marrowstim Concentration System, Biomet Biologics, Inc., 20 pages (REV Feb. 15, 2008).
Marx, Gerard, et al., “Heat Denaturation of Fibrinogen to Develop a Biomedical Matrix.” Journal of Biomedical Materials Research Part B: Applied Biomaterials (Apr. 2007) pp. 49-57.
Masri, Marwan A., et al. “Isolation of Human Fibrinogen of High Purity and in High Yield Using Polyethylene Glycol 1000.” Thromb Haemostas (Struttgart) (1983) vol. 49 (2); pp. 116-119.
Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. “Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment.” Wein Med Woschtr 122 (37 1972): 517-523.
Minntech® Filtration Technologies Group, “Hemocor HPH® Hemoconcentrator,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/hph/index.html, printed Jul. 15, 2004 (2 pages).
Minntech® Filtration Technologies Group, “Medical Applications: Blood Filtration” Minntech Corporation (2004); http://www.minntech.com/ftg/industries/medical/blood—filter.html, printed Jul. 15, 2004 (1 page).
Minntech® Filtration Technologies Group, “Renaflo® II Hemofilter,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/renaflo/index.html, printed Jul. 15, 2004 (2 pages).
Molnar, Amy, “Stem Cells from Muscles Can Repair Cartilage, Study Finds Genetically Engineered Muscle-Derived Stem Cells Improved Cartilage Repair in Rats”, American College of Rheumatology, (2005).
Moretz, W., Jr., J Shea Jr., J. R. Emmett, and J Shea. “A simple autologous fibrinogen glue for otologic surgery.” Otolaryngol Head Neck Surg 95 (1 1986): 122-4.
Nakagami, Hironori, et al., “Novel Autologous Cell Tehrapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells,” Angiogenesis by Adipose Tissue-Derived Cells, (2005) pp. 2542-2547, American Heart Association, Inc.
Nathan, Suresh et al., “Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue,” Tissue Engineering, vol. 9, No. 4 (2003) pp. 733-744 Mary Ann Liebert, Inc.
Nilsson, et al., “Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs,” The Journal of Bone and Joint Surgery, vol. 68 B., No. 4, Aug. 1986.
Orphardt, Charles E., “Denaturation of Proteins,” Virtual Chembook, Elmhurst College (2003) 3 pages. http://www.elmhurst.edu/˜chm/vchembook/568denaturation.html (web accessed Mar. 9, 2011).
Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203-209, Feb. 1994, Dean M. Toriumi, M.D., et al., “Surgical Tissue Adhesives in Otolaryngology—Head and Neck Surgery”.
Parker, Anna M., et al., Adipose-derived stem cells for the regeneration of damaged tissues, Expert Opinion, Cell- & Tissue-based Therapy, Expert Opin. Biol. Ther. (2006) pp. 567-578 Informa UK Ltd.
Planat-Bénard, V., et al., “Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells,” Adipose-Derived Cell Cardiomyocyte (2004) pp. 223-229 American Heart Association, Inc.
Ponticiello, Michael S., “A Rapid Technique for the Isolation and Concentration of Stem Cells from Human Bone Marrow”, Cell Factor Technologies, Inc. (2006) 2 pages.
Rangappa, Sunil, M.D., “Transformation of Adult Mesenchymal Stem Cells Isolated From the Fatty Tissue Into Cardiomyocytes,” Adult Stem Cells Transformed into Cardiomyoctyes, (2003) pp. 775-779 Ann Thorac Surg.
Rigotti, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Pub. 2005) pp. 1409-1422.
Rubin, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (2007) pp. 1423-1424.
Sanal, M. “Does fibrin glue cause foreign body reactions? [letter].” Eur J Pediatr Surg 3 (3 1993): 190 (1 page).
Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. “Does fibrin glue cause foreign body reactions?” Eu r J Pediatr Surg 2 (5 1992): 285-6.
Schmidt, K.G., et al., “Labelling of Human and Rabbit Platelets with Indium-Oxine Complex”, 23:97-106 (1979).
Schmidt, K.G., et al., “Preparation of Platelet Suspensions from Whole Blood in Buffer”, Scand. J. Hoemato, 23:88-96 (1979).
Schäffler, Andreas, et al., “Concise Review: Adipose Tissue-Derived Stromal Cells—Basic and Clinical Implications for Novel Cell-Based Therapies,” Tissue-Specific Stem Cells, Stem Cells® (2007) pp. 818-827 AlphaMed Press.
Semple, Elizabeth, PhD, et al. “Quality of Thrombin Produced From the Patient's Own Plasma Using the TPD Tradmark in Here, a New Thrombin-Processing Device.” Journal of American Society of Extra-Corporeal Technology. JECT: 2005; 37:196-200.
Sierra, D. H. “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications.” J Biomater Appl 7 (4 1993): 309-52.
Sigma-Aldrich® Alkaline Phosphatase (Procedure No. 85), drug fact sheet, (2003) pp. 1-2, Sigma-Aldrich, Inc.
Silver, Frederick H., et al., “Review Preparation and use of fibrin glue in surgery.” Biomaterials 16 (1995) pp. 891-903.
Solem, Jan Otto, et al., “Hemoconcentration by Ultrafiltration During Open-Heart Surgery,” Scand J Thor Cardiovasc Surg 22:271-274, 1988.
Sutton, Robin G., et al. “Comparison of Three Blood-Processing Techniques During and After Cardiopulmonary Bypass.” Ann Thorac Surg (1993) vol. 56; pp. 941-943.
Swift, Mathew J., et al., “Characterization of Growth Factors in Platelet Rich Plasma,” 1-Cell Factor Technologies, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Symphony II Platelet Concentrate System/PCS brochure; “Increasing bone graft bioactivity through reproducible concentrations of natural growth factors,” DePuy (Jan. 2003).
Takahashi, Kazutoshi et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, (2007) pp. 1-12, Elsevier Inc.
The American Journal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr., M.D., et al., “Autologous Fibrin Glue: The Last Step in Operative Hemostatis”.
The American Surgeon, vol. 55, pp. 166-168, Mar. 1989, William D. Spotnitz, M.D., et al., “Successful Use of Fibrin Glue During 2 Years of Surgery at a University Medical Center”.
The Sports Medicine Center, “Knee Cartilage Implantation”, Carticel™, “Autologous Cultured Chondrocyte Implantation”, http://www.orthoassociates.com/carticel.htm (printed Apr. 6, 2006).
The Stone Clinic, “Platelet Rich Plasma (PRP)”, web site printed May 2006.
Vox Sanquinis, vol. 68: 82-89, Feb. 1995, Boomgaard Et. al, Pooled Platelet Concentration Prepred by the . . . .
Weis-Fogh, U. S. “Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system.” Eur Surg Res 20 (5-6 1988): 381-9.
Weisman, MD., Robert A., “Biochemical Characterization of Autologous Fibrinogen Adhesive,” Laryngoscope 97: Oct. 1987; pp. 1186-1190.
Wiseman, David M., David T. Rovee, and Oscar M. Alverez. “Wound Dressings: Design and Use.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 562-580. 1st ed., Vol. Philadelphia: W. B. Saunders Company, 1992).
Woodell-May, et al., “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting,” Scientific Foundation, Journal of Carniofacial Surgery 16(5):749-756 (Sep. 2005).
Written Opinion of the International Preliminary Examining Authority mailed Mar. 17, 2009 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
Yoon, Eulsik, M.D., Ph.D., et al., “In Vivo Osteogenic Potential of Human Adipose-Derived Stem Cells/Poly Lactide-Co-Glycolic Acid Constructs for Bone Regneration in a Rat Critical-Sized Calvarial Defect Model,” Tissue Engineering, vol. 13, No. 3 (2007) pp. 619-627 Mary Ann Liebert, Inc.
Zhang, Duan-zhen, et al., “Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction,” Chinese Medical Journal, vol. 120, No. 4 (2007) pp. 300-307 General Hospital of Shenyang Military Region, Shenyang, China.
Zuk, Patricia A., Ph.D., “Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies,” Tissue Engineering, vol. 7, No. 2, (2001) pp. 211-228 Mary Ann Liebert, Inc.
“Caps for Corning® and Costar® Plastic Labware,” Technical Bulletin. (Dec. 2008) Corning, Incorporated.
“Centrifuge Tubes” Corning Costar brochure. 1996/1997 Catalog pp. 76-77.
“Clotalyst® Autologous Clotting Factor” brochure. (Aug. 15, 2008) Biomet Biologics.
“Corning® 15 and 50 mL Centrifuge Tubes,” Life Sciences. (Jun. 2005) Corning Incorporated.
“Letter CryoSeal FS System. Vaccines, Blood & Biologics,” letter. (Jul. 26, 2007) FDA U.S. Food and Drug Administation. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm091631.htm (Web accessed Aug. 12, 2011).
“Plasmax® Plasma Concentration System” brochure. (Jun. 15, 2008) Biomet® Biologics.
“Prosys PRP Kit,” brochure Tozai Holdings, Inc. http://tozaiholdings.en.ec21.com/Prosys—PRP—Kit--5467051—5467061.html Printed from Web Aug. 24, 2011.
“Prosys PRP Kit,” Tozai Holdings, Inc. EC21 Global B2B Marketplace http://www.ec21.com/product-details/Prosys-PRP-Kit--5467061.html Printed from Web Jul. 18, 2011.
DeUgarte, M.D., Daniel A., et al., “Future of Fat as Raw Material for Tissue Regeneration,” (Feb. 2003) pp. 215-219, Lippincott Williams & Wilkins, Inc.
GPS®ll System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Biomet Biologics (Jul. 15, 2006) 16 pages.
International Preliminary Report on Patentability mailed Jan. 26, 2012 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
International Search Report and Written Opinion mailed Aug. 9, 2011 for PCT/US2011/031954 claiming benefit of U.S. Appl. No. 12/758,127, filed Apr. 12, 2010.
Rigotti, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1409-1422.
Sanal, M. “Does fibrin glue cause foreign body reactions? [letter].” Eur J Pediatr Surg 3.(1992): 190 (1 page).
Japanese Office Action mailed Sep. 9, 2014 for Japan Patent Application No. 2012-520742,which claims benefit of PCT/US2010/041942 filed Jul. 14, 2010, which claims benefit of U.S. Appl. No. 12/504,413, filed Jul. 18, 2009.
Chinese Office Action mailed Jun. 30, 2014 for Chinese Patent Application No. 201080019707.7, which claims benefit of PCT/US2010/029957 filed Apr. 5, 2010, which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
Japanese Office Action mailed Sep. 9, 2014 for Japan Patent Application No. 2012-520742,which claims benefit of PCT/US2010/041942 filed Jul. 14, 2010, which claims benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
Minivalve international: duckbill valves—du 054.001 sd, <http://www.minivalve.com/htm/DV054.htm>, Accessed Jun. 30, 2014, 1 page.
Momentive Silopren*LSR 2050, Jun. 30, 2014, 3 pages.
Vernay Product Information Sheet, Umbrella Check Valve, Part No. V251010200, Jul. 2013, 2 pages.
Chinese Office Action mailed Nov. 21, 2014 for Chinese Patent Application No. 201280030026.X.
Related Publications (1)
Number Date Country
20110014705 A1 Jan 2011 US